Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.57 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13454924 | 0.88 | PI4KA (0.62) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL9791716 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL15425667 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL15426678 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL10240316 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL15426675 | 0.85 | ADORA2A (0.76) | ADORA2AADORA1ADORA3 | |
| SCHEMBL15425652 | 0.85 | ADORA2A (0.76) | ADORA2AADORA1ADORA3 | |
| SCHEMBL6746341 | 0.84 | PI4KA (0.56) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL12200089 | 0.82 | ADORA3 (0.69) | ADORA2AADORA1ADORA3PI4KAPI4K2B | |
| SCHEMBL15144301 | 0.82 | ADORA3 (0.69) | ADORA2AADORA1ADORA3PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183224-B2 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090062314-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7423144-B2 | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062314-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.